M&A

As QDRO Acquisition Corp. unbundles its shares and warrants, the SPAC signals its readiness to find a disruptive technology firm for its $200M war chest.

With a new chairman known for strategic acquisitions, LeoLabs is signaling an aggressive push into missile defense and a new era as a defense 'neoprime'.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

Abry Private Debt's latest acquisition with Coller Capital is more than a deal; it's a sign of the explosive growth in the private credit secondaries market.

After private rejections, Dream Finders Homes takes its acquisition offer public, putting pressure on Beazer's board amid the rival's financial struggles.

Fast-growing café Maman gets a fresh infusion of capital via a rare continuation vehicle, setting the stage for major national and international expansion.

As it nears $10B in assets, investment firm Disruptive hires a top tech advisor, signaling a new phase of strategic growth for its unique investment model.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

The investment bank reports a 100% revenue surge, raises dividends, and outpaces rivals, signaling a potential renaissance for the entire M&A sector.

Backed by activist investor Irenic Capital, a new $220M blank-check firm hits Nasdaq, aiming to acquire a target in the aerospace or industrial sectors.

Just seven years after its founding, IEQ Capital sees four founders named to Forbes' elite list. Here's how they built a $42 billion wealth powerhouse.

Western Metallica's deal with Emerita expires, but a crucial three-year permit renewal for its Nueva Celti copper project signals a strategic reset.

Christopher Kilpatrick's 2026 departure from Western Asset's HIX fund is part of a larger strategic personnel shift at parent company Franklin Templeton.

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Transom Capital Group appoints Luke Dauch, a decade-long J.P. Morgan banker, to bolster its deal origination in a competitive middle-market landscape.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

The oil producer's new BBB- ratings signal deep financial strength, unlocking lower borrowing costs, enhanced strategic options, and greater shareholder value.